A collaboration between Saïd M. Sebti, Ph.D., chair of Moffitt Cancer Center's Drug Discovery Department, and Michele Pagano, M.D., chair of the Department of Biochemistry and Molecular Pharmacology ...
Two nonrandomized, open-label phase II subprotocols within the context of the NCI-MATCH trial targeted PTEN tumor alterations in patients with advanced relapsed/refractory solid tumors, lymphoma, or ...
Truqap with Zytiga and ADT improved radiographic progression-free survival in patients with PTEN-deficient prostate cancer compared to placebo. The CAPitello-281 trial involved 1,012 patients, showing ...
How Does Truqap Work in HR-Positive Breast Cancer? Some people with HR-positive breast cancer also have changes in certain genes called PIK3CA, AKT1, or PTEN. When there is a change in the AKT1 gene, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results